A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Shrivastava, Meena
- Role of Ascorbic Acid Supplementation on Prevention of Olanzapine Induced Metabolic Side Effects in Schizophrenic Patients
Authors
1 Department of Pharmacology. Smt. Kashibai Navale Medical College & Hosp. Narhe Campus, Dhayari Phata, Pune-411041, IN
2 Department of Pharmacology Indira Gandhi Govt. Medical College, Nagpur, IN
3 Department of Psychiatry Indira Gandhi Govt. Medical College, Nagpur, IN
Source
Indian Journal of Public Health Research & Development, Vol 2, No 1 (2011), Pagination: 12-16Abstract
Schizophrenia is one of the most debilitating disorders with devastating effects on its victims and their families. Atypical antipsychotics (AAPs) because of their superior efficacy, reduced side effects,&better compliance, have rapidly become the mainstay of treatment. However, these AAPs have unique side effect profile like weight gain, hyperglycemia, and hyperlipidemia. Although preliminary data suggest benefit of vitamin C in improving the lipid and glucose dysregulation, whether vitamin C as an antioxidant has any effect on improving drug induced metabolic derangements has not been clarified yet. Therefore, this prospective clinical trial has been carried out to determine the impact of vitamin C as an antioxidant in modifying these parameters in schizophrenic patients. Among 30 newly diagnosed DSM-IV patients of schizophrenia enrolled, mean body weight, BMI, blood sugar, and lipid profile were significantly increased from baseline to 6 and 12 weeks after treatment with olanzapine(p <0.001). However, there were no statistically significant differences in these parameters between patients who received only olanzapine and those who received both olanzapine and vitamin C. Thus, vitamin C as an antioxidant does not modify the metabolic side effect profile of olanzapine.Keywords
Schizophrenia, Olanzapine, Vitamin C, Blood Sugar, Lipid ProfileReferences
- Stahl SM. Essential psychopharmacology neuroscientific basis and practical application. 2nd ed. Cambridge University Press; 2004.
- American psychiatric association practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154:1-63.
- Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61(10):111-61.
- Lieberman JA. Atypical antipsychotic drugs as a firstline treatment of schizophrenia: a rational and hypothesis. J Clin Psychiatry 1996; 57(11):68-71.
- Farewell WR, Stump TE, Wang J, Tafesse E, L’Italien GL, Tierney, WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 2004; 19:1200-05.
- Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003; 23(8):1037-43.
- Ganguli R, Brar JS, Ayrton Z. Weight gain over four months in schizophrenia patients: a comparison of olanzapine and risperidone. Schizophrenia Research 2001; 49:261-67.
- Koro CE, Fedder DO, L’Italien GL, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenia patients. Arch Gen Psychiatry 2002; 59:1021-26.
- Dai S, McNeill JH. Ascorbic acid supplementation prevents hyperlipidemia and improves myocardial performance in streptozotocin-diabetic rats. Diabetes Res Clin Pract 1995; 27(1):11-18.
- Vinson JA, Sheu-Ju Hu, Jan S, Stansk NM. A citrus extract plus ascorbic acid decreases lipids, lipid peroxides, lipoprotein oxidative susceptibility, and atherosclerosis in hypercholesterolemic hamsters J Agri Food Chem 1998; 46(4); 1453-59.
- Flier JS, Flier EM. Obesity. In: Harrison¢s principles of internal medicine. 16th ed. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo, DL, Jameson JL. editors, New York: McGraw Hill, 2005,1311-19.
- Miskiewicz SJ. Quantitative estimation of glucose by GOD/POD method. Clin Chem 1973; 19:253-54.
- Tarbutton PN, Gunter CR. Quantitative estimation of serum total cholesterol. Clin Chem 1974; 20:724-26.
- Foosati P. Quantitative estimation of serum triglyceride. Clin Chem 1982; 28:2077-79.
- Finley PR. Quantitative estimation of serum HDL cholesterol. Clin Chem 1978; 24:931-34.
- Rifai N, Warnick GR. Lipids, lipoproteins, apolipoprotiens, and other cardiovascular risk factors. In: Tietz textbook of clinical chemistry and molecular diagnostics. 4th ed. Burtis CA, Ashwood ER, Bruns DE editors, An Imprint of Elseview, 2006:903-81.
- Thara R, Padmavati R, Shrinivasan TN. Schizophrenia. The British Journal of Psychiatry 2004; 184:366-73.
- Baldessarini RJ, Tarazi I. Pharmacotherapy of psychosis and mania. In: Goodman and Gilman’s the pharmacological basis of therapeutics. 11th ed. Brunton LL, Lazo JS, Pasrker KL, editors, McGraw Hill, 2005, 1753-71.
- Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-95.
- Conley RR, Mahmoud R. A randomized double blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158:765-74.
- Garyfallos G, Dimelis D, Kouniakis P., Sidiropoulos N, Karastergiou A, Lavrentiadis G, et al. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. J European Psychiatry 2003; 18:320- 21.
- Lindenmayer JP, Czobar P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160:290-96.
- Koro CE, Fedder DO, L’Italien GL, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenia patients. Arch Gen Psychiatry 2002; 59:1021-26.
- Simon JA, Hudes ES. Relation of serum ascorbic acid to serum lipids and lipoproteins in US adults. Journal of the American College of Nutrition 1998; 17(3):250- 55.
- Vinson JA, Sheu-Ju Hu, Jan S, Stansk NM. A citrus extract plus ascorbic acid decreases lipids, lipid peroxides, lipoprotein oxidative susceptibility, and atherosclerosis in hypercholesterolemic hamsters.J Agri Food Chem 1998; 46(4); 1453-59.
- The Psychomotor Effects of Levocetirizine - a Second Generation Antihistamine in Healthy Volunteers
Authors
1 Pharmacology Rajiv Gandhi Institute of Medical Sciences (RIMS) Adilabad A.P., IN
2 Pharmacology Rajiv Gandhi Institute of Medical Sciences (RIMS) Adilabad, A.P., IN
3 Pharmacology Wasantrao Naik Medical College Yeotmal, M.S., IN
4 Pharmacology Indira Gandhi Government Medical College Nagpur, M.S., IN
Source
Indian Journal of Public Health Research & Development, Vol 2, No 1 (2011), Pagination: 44-47Abstract
Background
Levocetirizine, a new second generation antihistamine which is claimed to be non-sedative in western studies is an R-enantiomer of cetirizine. In Indian context there is little literature available about its impact on psychomotor performance. That's why present study was planned to exclude the possibility of adverse effect of levocetirizine on psychomotor performance in Indian conditions.
Materials and methods
In this double blind, placebo controlled, cross over study, 24 healthy volunteers performed various objective and subjective psychometric test after single dose of levocetirizine 5 mg, chlorpheniramine 4 mg or placebo at 0hrs, 2hrs and 4 hrs intervals. The test battery included was - six digit cancellation test, digit symbol substitution test, arithmetic ability, critical flicker fusion, serial verbal learning, hand steadiness test and three different visual analogue scales.
Results
In the present study levocetirizine was statistically similar with chlorpheniramine on six digit cancellation test (p value <0.05), however it did not impair any other psychomotor performance test and was similar to placebo. Chlorpheniramine impaired performance significantly on all the objective and subjective psychomotor test at both time intervals.
Conclusion
It can be concluded that levocetirizine in 5mg dose is free from the negative effects of the previous generation of antihistamines and do not impair psychomotor performance in Indian conditions also.
Keywords
Levocetirizine, Six Digit Cancellation Test, Psychomotor PerformanceReferences
- Murdoch, D., Goa, K.L., Keam, S.J. Desloratadine An update of its efficacy in the management of allergic disorders. Drugs 2003; 63 (19): 2051- 2077.
- Slater, J.W., Zechnich, A.D., Haxby, D.G. Second - generation antihistamines a comparative review. Drugs 1999; 57 (1): 31-47.
- Lawrence, M., Buske, D. Clinical comparison of histamine H1 - receptor antagonist drugs. J Allergy Clin Immunol 1996; 98 (6 pt 3): S 307 – S318.
- Verster, J.C., Volkerts, E.R., van Oosterwijck, A.W., Arab, M., Bijtjes, S.I., De Weert, A.M., Eijken, E.J., Verbaten, M.N. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003 ;111(3) : 623-7.
- Tashiro, M., Mochizuki, H., Iwabuchi, K., Sakurada, Y., Itoh, M. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 – receptor in human brain. Life Sci 2002 ; 72 : 409-414.
- Manual on Clinical Pharmacology. Workshop on clinical pharmacology, 2003. Post Grad 1nst Med Ed Res (PGIMER) Chandigarh.
- Stone, B.M. Pencil and paper tests-sensitivity to psychotropic drugs. Br J Clin Pharmacol 1984; 18 Suppl 1: 15S-20S.
- Manual Pharmatech. Techniques in pharmacology. Seth GS Med Coll and KEM Hosp Mumbai 1996.
- Marshall, S., Colon, E.A. Effects of a llergy season on mood and cognitive functions. Ann Allergy 1993; 71: 251-258.
- Aitken, R.C.B. Measurement of feelings using visual analogue scales. Proc Roy Soc Med 1969; 62: 989-993.
- Hindmarch, 1., Johnson, S., Meadows, R., Kirkaptrick, T., Shamsi, Z. The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and wheal and flare. Curr Med Res Opin 2001; 17 (4): 241 – 55.
- Gandon, J.M., Allain, H. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor function in healthy volunteers. Br J Clin Pharmacol 2002; 54: 51- 58.
- Clarke, C.H., Nicholson, A.N. Performance studies with antihistamines. Br J Clin Pharmacol 1978 ; 6 : 31-35.
- Meador, K.J., Ioring, D.W., Thompson, E.E., Thompson, W.O. Differential cognitive effects of terfenadine and chlorpheniramine. J Allergy Clin Immunol 1989; 84(3): 322-325.
- Khosla,P.P., Saha,N., Koul,A., Chakrabarti,A., Sankarnarayanan,A., Sharma,P.L. Effects of ranitidine alone and in combination with chlorpheniramine on histamine-induced wheal and flare and psychomotor performance. Indian J Physiol Pharmacol 1993; 37(2): 132-4.
- Simons, F.E., Reggin, J.D., Roberts, J.R., Simons, K.J. Benefit/risk ratio of the antihistamines (H1-receptor antagonists) terfenadine and chlorpheniramine in children. Pediatr 1994; 124(6): 979-83.